

Announcement from Annual General Meeting, also first control meeting, in LIDDS AB (publ), held on 28 May 2025

An Annual General Meeting, also the first control meeting, was held in LIDDS AB (publ) (the “Company”) on 28 May 2025. A summary of the decisions made at the meeting follows below. All resolutions have been made with the required majority and in accordance with the proposals presented to the meeting.

Resolution on whether the Company should enter into liquidation or continue operations

The Annual General Meeting resolved, in accordance with the primary proposal from the Board of Directors, that the Company shall continue its operations and not enter into liquidation.

The resolution entails that the General Meeting shall be convened within eight months from this first control meeting to re-examine the question of whether the Company should enter into liquidation (second control meeting). Prior to the second control meeting, the Board of Directors must prepare a new second balance sheet for liquidation purposes and have it reviewed by the Company's auditor.

Adoption of the income statement and the balance sheet as well as the consolidated income statement and the consolidated balance sheet and discharge from liability

The Annual General Meeting adopted the income statement and the balance sheet as well as the consolidated income statement and the consolidated balance sheet for the financial year 2024. The Annual General Meeting further resolved to grant each member of the Board and the CEO discharge from liability for the financial year 2024.

Resolution on disposition of the Company's result

The Annual General Meeting resolved that no dividend shall be paid for the financial year 2024 and that the Company's available funds shall be carried forward into new accounts.

Board members, Chairman of the Board and auditors

The Board shall consist of four ordinary members elected by the General Meeting without deputies. The Annual General Meeting resolved to re-elect Daniel Lifveredson, Torbjörn Browall, Lars-Inge Sjöqvist and Stefan Rehnmark as ordinary Board members. More information regarding the Board members can be found on the Company's website, www.liddspharma.com.

Daniel Lifveredson was re-elected as Chairman of the Board.

The Company shall have one auditor without a deputy auditor. The Annual General Meeting resolved to re-elect the registered auditing firm BDO Göteborg AB with the certified auditor Katarina Eklund as auditor in charge.

Determination of remuneration to the Board members and the auditor

The Annual General Meeting resolved that a fee of SEK 112,500 shall be paid to the Chairman of the Board and that a fee of SEK 56,250 shall be paid to each of the other members elected by the meeting for the entire term of office.

Furthermore, the Annual General Meeting resolved that remuneration to the auditor shall be paid in accordance with approved invoice.

Resolution on the adoption of instructions for the appointment of the Nomination Committee

The Annual General Meeting resolved to adopt principles for the appointment of the Nomination Committee ahead of the 2026 Annual General Meeting, in accordance with the proposal of the Nomination Committee. It was further resolved that no fees shall be paid to the members of the Nomination Committee.

Authorisation on new issue

The Annual General Meeting resolved to authorise the Board of Directors to, during the period until the next Annual General Meeting, on one or more occasions, resolve on new issue of shares, and/or convertibles with or without deviation from shareholders' preferential rights and with or without provisions regarding non-cash consideration, set-off of claims against the Company or otherwise with conditions. The number of shares that may be issued and the number of shares to which conversion may take place may not exceed thirty-five percent of the total number of shares in the Company at the time of the Annual General Meeting. The issue price shall be market-based.

The purpose of the authorisation is to be able to raise working capital with the aim of strengthening the ownership structure, accelerating development projects, and enabling issuance to industrial partners within the framework of collaborations and alliances.

The Chairman of the Board and the CEO were further authorised to make the minor adjustments to the resolutions of the meeting that may prove necessary in connection with registration with the Swedish Companies Registration Office and Euroclear Sweden AB.

The resolutions in their entirety

The adopted resolutions in their entirety can be found on the Company's website, www.liddspharma.com.

For additional information, please contact

Mats Wiking, CEO and CFO
Phone: +46 (0)70 620 04 00
E-mail: mats.wiking@liddspharma.com

Daniel Lifveredson, Chairman of the Board
Telefon: +46 (0) 70-916 21 01
Email: d.li@excore.com

LIDDS' Certified Adviser is Redeye AB

LIDDS in brief:

LIDDS is a Swedish pharmaceutical company focused on the development of oncology drugs. LIDDS has a proprietary drug delivery technology, NanoZolid®, on which several projects are based. With NanoZolid, LIDDS can formulate drugs for local/intratumoral administration, with a maintained and controlled release and with minimal negative side-effects. In addition to these projects, LIDDS develops proprietary drug candidate NOV202 that have shown very good results in pre-clinical studies. The company is listed on Nasdaq First North Growth market.

Attachments

Announcement from Annual General Meeting, also first control meeting, in LIDDS AB (publ), held on 28 May 2025

Stämmoprotokoll Årsstämma i LIDDS AB (publ) (2025) (SW 2025 05 28)